ArticleClinical and vaccine immunology : CVI2007
A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis.
Article in Clinical and vaccine immunology : CVI, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Proteome Profile Changes Induced by Heterologous Overexpression ofBiomolecules · 2022Article
- GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.Clinical and vaccine immunology : CVI · 2017Article
- Article
- Dendritic cell targeted vaccines: Recent progresses and challenges.Human vaccines & immunotherapeutics · 2016Article
- From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.Clinical & translational immunology · 2015Article
- Vaccines for TB: Lessons from the Past Translating into Future Potentials.Journal of immunology research · 2015Review
- Dendritic cell-targeted vaccines--hope or hype?Nature reviews. Immunology · 2014Review
- TLR2 engagement on CD4(+) T cells enhances effector functions and protective responses to Mycobacterium tuberculosis.European journal of immunology · 2014Article
- Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis.Tuberculosis (Edinburgh, Scotland) · 2014Article
- Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines.Frontiers in immunology · 2014Review
- Targeting TLR2 for vaccine development.Journal of immunology research · 2014Review
- BCG vaccine mediated reduction in the MHC-II expression of macrophages and dendritic cells is reversed by activation of Toll-like receptors 7 and 9.Cellular immunology · 2014Article
- Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.The Journal of infectious diseases · 2013Article
- Vaccination with recombinant Mycobacterium tuberculosis PknD attenuates bacterial dissemination to the brain in guinea pigs.PloS one · 2013Article
- Impact of toll-like receptor 2 deficiency on immune responses to mycobacterial antigens.Infection and immunity · 2011Article
- Mycobacterium tuberculosis lipoproteins directly regulate human memory CD4(+) T cell activation via Toll-like receptors 1 and 2.Infection and immunity · 2011Article
- A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.Science translational medicine · 2010Article
- TLR-2 independent recognition of Mycobacterium tuberculosis by CD11c+ pulmonary cells from old mice.Mechanisms of ageing and development · 2010Article
- The contribution of Toll-like receptor 2 to the innate recognition of a Leishmania infantum silent information regulator 2 protein.Immunology · 2009Article
- Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A fusion protein designated CSU-F36 was constructed that consisted of acylated Rv1411, a potent Toll-like receptor-2 agonist, fused to ESAT-6, a well-characterized immunogenic protein from Mycobacterium tuberculosis. The CSU-F36 fusion protein strongly induced interleukin 12 secretion from macrophages and induced the increased accumulation of CD4 T cells capable of secreting gamma interferon in the lungs of infected mice. These mice were significantly protected from low-dose aerosol challenge with M. tuberculosis, even with CSU-F36 delivered in a simple depot material. This "natural adjuvant"-containing system could potentially bypass the need for more expensive TH1-inducing adjuvants and could be applied to many mycobacterial proteins to provide effective and cheap new vaccines against tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.